Differential diagnosis and management of Behçet syndrome

Nature Reviews Rheumatology

Volumn 9, Issue 2, 2013, Pages 79-89

  Haskard, Dorian O ^a   Ambrose, Nicola L ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; AZATHIOPRINE; BENZATHINE PENICILLIN; C REACTIVE PROTEIN; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID; PEGINTERFERON ALPHA2A; PLACEBO; THALIDOMIDE; ZINC SULFIDE;

ARTHRITIS; BEHCET DISEASE; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOCARDITIS; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; EYE DISEASE; EYE INFLAMMATION; GENITAL ULCER; HEADACHE; HEART ANEURYSM; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; INTRACARDIAC THROMBOSIS; INTRACRANIAL ANEURYSM; IRRITABLE COLON; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; MOUTH HYGIENE; MOUTH ULCER; NEUROLOGICAL COMPLICATION; PATHERGY TEST; PERICARDITIS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RETINA MACULA EDEMA; REVIEW; SAPHO SYNDROME; SENSITIVITY AND SPECIFICITY; SKIN DEFECT; SPONDYLARTHRITIS; SYNDROME DELINEATION; THROMBOSIS; UVEITIS;

AZATHIOPRINE; BEHCET SYNDROME; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PREVALENCE; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873412920     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.156     Document Type: Review

References (109)

1. Feigenbaum, A. Description of Behçet's syndrome in the Hippocratic third book of endemic diseases. Br. J. Ophthalmol. 40, 355-357 (1956).
2. Zouboulis, C. C. & Keitel, W. A historical review of early descriptions of Adamantiades-Behçet's disease. J. Invest. Dermatol. 119, 201-205 (2002).
3. Adamantiades, B. A case of relapsing iritis with hypopyon [Greek]. Archia Iatrikis Etairias, (Proceedings of the Medical Society of Athens) Athens, 586-593 (1930).
4. Behçet, H. Über rezidivierende aphthose, durch ein virus verursachte geschwüre am mund, am auge und an der genitalien [German]. Dermatol. Wochenschr. 105, 1152-1157 (1937).
5. Mizuki, N. et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat. Genet. 42, 703-706 (2010).
6. Remmers, E. F. et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat. Genet. 42, 698-702 (2010).
7. Direskeneli, H. Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann. Rheum. Dis. 60, 996-1002 (2001).
8. Kapsimali, V. D., Kanakis, M. A., Vaiopoulos, G. A. & Kaklamanis, P. G. Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. Clin. Rheumatol. 29, 1211-1216 (2010).
9. Drenth, J. P. & van der Meer, J. W. Hereditary periodic fever. N. Engl. J. Med. 345, 1748-1757 (2001).
10. Gul, A. Behçet's disease as an autoinflammatory disorder. Curr. Drug Targets Inflamm. Allergy 4, 81-83 (2005).
11. Verity, D. H., Marr, J. E., Ohno, S., Wallace, G. R. & Stanford, M. R. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54, 213-220 (1999).
12. Kural-Seyahi, E. et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82, 60-76 (2003).
13. Davatchi, F. et al. Behçet's disease in Iran: analysis of 6500 cases. Int. J. Rheum. Dis. 13, 367-373 (2010).
14. Nakae, K. et al. in Behçet's Disease (eds Godeau, P. & Wechsler, B.) 145-151 (Excerpta Medica, Amsterdam, 1993).
15. Zhang, Z., Peng, J., Hou, X. & Dong, Y. Clinical manifestations of Behçet's Disease in Chinese patients. APLAR J. Rheumatol. 9, 244-247 (2006).
16. Bang, D. et al. Epidemiologic and clinical survey of Behçet's disease in Korea: the first multicenter study. J. Korean Med. Sci. 16, 615-618 (2001).
17. Altenburg, A. et al. Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany-current pathogenetic concepts and therapeutic possibilities [German]. J. Dtsch Dermatol. Ges. 4, 49-64 (2006).
18. Yurdakul, S. et al. The prevalence of Behçet's syndrome in a rural area in northern Turkey. J. Rheumatol. 15, 820-822 (1988).
19. Azizlerli, G. et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int. J. Dermatol. 42, 803-806 (2003).
20. Chamberlain, M. A. Behçet's syndrome in 32 patients in Yorkshire. Ann. Rheum. Dis. 36, 491-499 (1977).
21. Calamia, K. T. et al. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum. 15, 600-604 (2009).
22. Davatchi, F. et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran J. Rheumatol. 35, 1384 (2008).
23. Yurdakul, S., Hamuryudan, V. & Yazici, H. Behçet syndrome. Curr. Opin. Rheumatol. 16, 38-42 (2004).
24. Bernabé, E., Marcenes, W., Mather, J., Phillips, C. & Fortune, F. Impact of Behçet's syndrome on health-related quality of life: influence of the type and number of symptoms. Rheumatology (Oxford) 49, 2165-2171 (2010).
25. Gurler, A., Boyvat, A. & Türsen, U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med. J. 38, 423-427 (1997).
26. Karincaoglu, Y. et al. Demographic and clinical properties of juvenile-onset Behçet's disease: A controlled multicenter study. J. Am. Acad. Dermatol. 58, 579-584 (2008).
27. Soy, M., Erken, E., Konca, K. & Ozbek, S. Smoking and Behçet's disease. Clin. Rheumatol. 19, 508-509 (2000).
28. Diri, E. et al. Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: a controlled and masked study. Ann. Rheum. Dis. 60, 1074-1076 (2001).
29. Hatemi, G. et al. The pustular skin lesions in Behçet's syndrome are not sterile. Ann. Rheum. Dis. 63, 1450-1452 (2004).
30. Tugal-Tutkun, I., Onal, S., Altan-Yaycioglu, R., Huseyin Altunbas, H. & Urgancioglu, M. Uveitis in Behçet disease: an analysis of 880 patients. Am. J. Ophthalmol. 138, 373-380 (2004).
31. Kidd, D. The prevalence of headache in Behçet's syndrome. Rheumatology (Oxford) 45, 621-623 (2006).
32. Kidd, D., Steuer, A., Denman, A. M. & Rudge, P. Neurological complications in Behçet's syndrome. Brain 122, 2183-2194 (1999).
33. Akman-Demir, G., Serdaroglu, P. & Tasçi, B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122, 2171-2182 (1999).
34. Hirohata, S. Histopathology of central nervous system lesions in Behçet's disease. J. Neurol. Sci. 267, 41-47 (2008).
35. Hadfield, M. G., Aydin, F., Lippman, H. R., Kubal, W. S. & Sanders, K. M. Neuro-Behçet's disease. Clin. Neuropathol. 15, 249-255 (1996).
36. Siva, A. et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J. Neurol. 248, 95-103 (2001).
37. Pollak, L., Luxon, L. M. & Haskard, D. O. Labyrinthine involvement in Behçet's syndrome. J. Laryngol. Otol. 115, 522-529 (2001).
38. Jäger, H. R., Albrecht, T., Curati-Alasonatti, W. L., Williams, E. J. & Haskard, D. O. MRI in neuro-Behçet's syndrome: comparison of conventional spin-echo and FLAIR pulse sequences. Neuroradiology 41, 750-758 (1999).
39. Akman-Demir, G. et al. Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch. Neurol. 53, 691-694 (1996).
40. Al-Araji, A. & Kidd, D. P. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 8, 192-204 (2009).
41. Yurdakul, S. et al. The arthritis of Behçet's disease: a prospective study. Ann. Rheum. Dis. 42, 505-515 (1983).
42. Khan, M. A. & van der Linden, S. M. A wider spectrum of spondyloarthropathies. Semin. Arthritis Rheum. 20, 107-113 (1990).
43. Dilsen N., Konice, M. & Aral, O. in Recent Advances in Behçet's Disease (eds Lehner, T. & Barnes, C. G.) 281-284 (Royal Society of Medicine Services, London, 1986).
44. Lee, S. S., Yoon, H. J., Chang, H. K. & Park, K. S. Fibromyalgia in Behçet's disease is associated with anxiety and depression, and not with disease activity. Clin. Exp. Rheumatol. 23, S15-S19 (2005).
45. Firestein, G. S. et al. Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease. Am. J. Med. 79, 65-72 (1985).
46. Colina, M., Govoni, M., Orzincolo, C. & Trotta, F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 61, 813-821 (2009).
47. Bayraktar, Y., Ozaslan, E. & Van Thiel, D. H. Gastrointestinal manifestations of Behçet's disease. J. Clin. Gastroenterol. 30, 144-154 (2000).
48. Hamdulay, S. S. et al. Wireless capsule endoscopy in the investigation of intestinal Behçet's syndrome. Rheumatology (Oxford) 47, 1231-1234 (2008).
49. Lee, S. K., Kim, B. K., Kim, T. I. & Kim, W. H. Differential diagnosis of intestinal Behçet's disease and Crohn's disease by colonoscopic findings. Endoscopy 41, 9-16 (2009).
50. Mehta, P., Laffan, M. & Haskard, D. O. Thrombosis and Behçet's syndrome in non-endemic regions. Rheumatology (Oxford) 49, 2003-2004 (2010).
51. Sarica-Kucukoglu, R. et al. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int. J. Dermatol. 45, 919-921 (2006).
52. Seyahi, E. & Yurdakul, S. Behçet's syndrome and thrombosis. Mediterr. J. Hematol. Infect. Dis. 3, e2011026 (2011).
53. Hamuryudan, V., Oz, B., Tüzün, H. & Yazici, H. The menacing pulmonary artery aneurysms of Behçet's syndrome. Clin. Exp. Rheumatol. 22 (Suppl. 34), 1-3 (2004).
54. Seyahi, E. et al. Atherosclerosis in Behçet's syndrome. Semin. Arthritis Rheum. 38, 1-12 (2008).
55. Geri, G. et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) 91, 25-34 (2012).
56. Cetinel, B., Obek, C., Solok, V., Yaycioglu, O. & Yazici, H. Urologic screening for men with Behçet's syndrome. Urology 52, 863-865 (1998).
57. Gul, A. & Ohno, S. HLA-B*51 and Behçet disease. Ocul. Immunol. Inflamm. 20, 37-43 (2012).
58. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 335, 1078-1080 (1990).
59. Davies, P. G., Fordham, J. N., Kirwan, J. R., Barnes, C. G. & Dinning, W. J. The pathergy test and Behçet's syndrome in Britain. Ann. Rheum. Dis. 43, 70-73 (1984).
60. Davatchi, F. et al. Diagnostic value of pathergy test in Behçet's disease according to the change of incidence over the time. Clin. Rheumatol. 30, 1151-1155 (2011).
61. Cakir, N. et al. Response to intradermal injection of monosodium urate crystals in Behçet's syndrome. Ann. Rheum. Dis. 50, 634-636 (1991).
62. Budak-Alpdogan, T. et al. Skin hyperreactivity of Behçet's patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders. Br. J. Rheumatol. 37, 1148-1151 (1998).
63. Saenz, A. et al. Pharmacotherapy for Behçet's syndrome. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD001084. http://dx.doi.org/10.1002/14651858.CD001084.
64. Mat, C. et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 45, 348-352 (2006).
65. Aktulga, E. et al. A double blind study of colchicine in Behçet's disease. Haematologica 65, 399-402 (1980).
66. Yurdakul, S. et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 44, 2686-2692 (2001).
67. Yazici, H. et al. A controlled trial of azathioprine in Behçet's syndrome. N. Engl. J. Med. 322, 281-285 (1990).
68. Melikoglu, M. et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J. Rheumatol. 32, 98-105 (2005).
69. Alpsoy, E. et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol. 138, 467-471 (2002).
70. Hamuryudan, V. et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128, 443-450 (1998).
71. Masuda, K. et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1, 1093-1096 (1989).
72. Sharquie, K. E., Najim, R. A. & Abu-Raghif, A. R. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. J. Dermatol. 29, 267-279 (2002).
73. Davies, U. M., Palmer, R. G. & Denman, A. M. Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double-blind trial. Br. J. Rheumatol 27, 300-302 (1988).
74. Al-Waiz, M. M., Sharquie, K. E., A-Qaissi, M. H. & Hayani, R. K. Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study. Dermatol. Online J. 11, 3 (2005).
75. Jorizzo, J. L., White, W. L., Wise, C. M., Zanolli, M. D. & Sherertz, E. F. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet's disease. J. Am. Acad. Dermatol. 24, 973-978 (1991).
76. Alpsoy, E., Zouboulis, C. C. & Ehrlich, G. E. Mucocutaneous lesions of Behçet's disease. Yonsei Med. J. 48, 573-585 (2007).
77. Addy, M., Carpenter, R. & Roberts, W. R. Management of recurrent aphthous ulceration. A trial of chlorhexidine gluconate gel. Br. Dent. J. 141, 118-120 (1976).
78. Meiller, T. F. et al. Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg. Oral Med. Oral Pathol. 72, 425-429 (1991).
79. Alpsoy, E., Er, H., Durusoy, C. & Yilmaz, E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch. Dermatol. 135, 529-532 (1999).
80. Alpsoy, E. et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol. 138, 467-471 (2002).
81. Saadoun, D. et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res. (Hoboken) 62, 1733-1738 (2010).
82. Hamuryudan, V. et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 40, 769-774 (1997).
83. Neri, P., Mariotti, C., Cimino, L., Mercanti, L. & Giovannini, A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int. Ophthalmol. 29, 127-133 (2009).
84. Ozyazgan, Y. et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br. J. Ophthalmol. 76, 241-243 (1992).
85. BenEzra, D. et al. Treatment of endogenous uveitis with cyclosporine, A. Transplant Proc. 20 (3 Suppl. 4), 122-127 (1988).
86. Arida, A., Fragiadaki, K., Giavri, E. & Sfikakis, P. P. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin. Arthritis Rheum. 41, 61-70 (2011).
87. Zaghetto, J. M. et al. Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study. Arq. Bras. Oftalmol. 73, 40-46 (2010).
88. Hamuryudan, V. et al. Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr. Med. Assoc. J. 4 (Suppl. 11), 928-930 (2002).
89. Sobaci, G. et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments. Ophthalmology 117, 1430-1435 (2010).
90. Onal, S. et al. Long-term efficacy and safety of low-dose and dose-escalating interferon α2a therapy in refractory Behçet uveitis. Arch. Ophthalmol. 129, 288-294 (2011).
91. Kötter, I. et al. Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin. Arthritis Rheum. 33, 311-319 (2004).
92. Kikuchi, H., Aramaki, K. & Hirohata, S. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. Adv. Exp. Med. Biol. 528, 575-578 (2003).
93. Suda, H. Low-dose weekly methotrexate therapy for progressive neuro-Behçet's disease [Japanese]. Nihon Rinsho Meneki Gakkai Kaishi 22, 13-22 (1999).
94. Ait Ben Haddou, E. H. et al. Neurological manifestations of Behçet's disease: evaluation of 40 patients treated by cyclophosphamide. Rev. Neurol. (Paris) 168, 344-349 (2012).
95. Kötter, I. et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin. Rheumatol. 25, 482-486 (2006).
96. Farah, S. et al. Behçet's syndrome: a report of 41 patients with emphasis on neurological manifestations. J. Neurol. Neurosurg. Psychiatry 64, 382-384 (1998).
97. Hosaka, A. et al. Long-term outcome after surgical treatment of arterial lesions in Behçet disease. J. Vasc Surg. 42, 116-121 (2005).
98. Ahn, J. K., Lee, Y. S., Jeon, C. H., Koh, E. M. & Cha, H. S. Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin. Rheumatol. 27, 201-205 (2008).
99. Hatemi, G. et al. EULAR recommendations for the management of Behçet disease. Ann. Rheum. Dis. 67, 1656-1662 (2008).
100. Karlidag, R. et al. Stressful life events, anxiety, depression and coping mechanisms in patients with Behçet's disease. J. Eur. Acad. Dermatol. Venereol. 17, 670-675 (2003).
101. Karatay, S. et al. Vitamin D status in patients with Behçet's disease. Clinics (Sao Paulo) 66, 721-723 (2011).
102. Cutolo, M., Plebani, M., Shoenfeld, Y., Adorini, L. & Tincani, A. Vitamin D endocrine system and the immune response in rheumatic diseases. Vitam. Horm. 86, 327-351 (2011).
103. Daikeler, T. et al. Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann. Rheum. Dis. 66, 202-207 (2007).
104. Hirano, T. et al. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod. Rheumatol. 22, 298-302 (2012).
105. Borhani Haghighi, A. & Safari, A. Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease. Med. Hypotheses 71, 156-157 (2008).
106. Shapiro, L. S., Farrell, J. & Haghighi, A. B. Tocilizumab treatment for neuro-Behçet's disease, the first report. Clin. Neurol. Neurosurg. 114, 297-298 (2012).
107. Tellier, Z. Intravenous immunoglobulin in eye involvement. Clin. Rev. Allergy Immunol. 29, 295-306 (2005).
108. Gül, A. et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann. Rheum. Dis. 71, 563-566 (2012).
109. Bhakta, B. B. et al. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38, 728-733 (1999).